Loren Data's SAM Daily™

SAMDAILY.US - ISSUE OF APRIL 30, 2020 SAM #6727
SPECIAL NOTICE

66 -- Application of Next Generation Sequencing

Notice Date

4/28/2020 2:06:27 PM
 

Notice Type

Special Notice
 

NAICS

334516 — Analytical Laboratory Instrument Manufacturing
 

Contracting Office

FDA OFFICE OF ACQ GRANT SVCS ROCKVILLE MD 20857 USA
 

ZIP Code

20857
 

Solicitation Number

FDA_1228061
 

Response Due

5/8/2020 10:00:00 AM
 

Archive Date

05/23/2020
 

Point of Contact

Yolanda Rankin
 

E-Mail Address

yolanda.rankin@fda.hhs.gov
(yolanda.rankin@fda.hhs.gov)
 

Description

Application of Next Generation Sequencing Technologies for Blood Safety-Procurement of Kits Reagents and support Intent to Sole Source FDA - 1228061 Date Posted:��������������� April 28, 2020 Response Date:����������� May 8, 2020 12:00 PM CST Classification Code:���� 6640 �-- Laboratory Equipment and Supplies NAICS Code:� 339999 � All Other Miscellaneous Manufacturing; with a Small Business Size � ������������������������������������� �Standard of 500 The U.S. Food and Drug Administration (FDA)/Center for Biologics Evaluation and Research (CBER) intends to award a sole source, firm fixed price purchase order to Oxford Nanopore Technologies, 1 Kendal Sq Building 200, Ste B2005, Cambridge, MA� 02139-1562, under the authority of FAR 13.106-1(b)(1), Only One Responsible Source and No Other Supplies or Services Will Satisfy Agency Requirements. Oxford Nanopore Technologies will provide Application of Next Generation Sequencing (NGS) Technologies for Blood Safety-Procurement of Kits Reagents and support.� The requested service is a direct follow-on to the existing consumables and support for the MinION NGS device that was procured in FY18 and FY19 which included a variety of flow cells, sequencing kits, software, and technical support.� CBER must utilize the same service, procedures, and expertise in order to ensure that results are comparable with the body of work currently being performed; ensuring consistency of maintaining the service. This notice is being published in accordance with Federal Acquisition Regulation (FAR) Part 5.101(a)(2) requiring the dissemination of information on proposed contract actions. This is a notice of intent to award a sole-source contract and is not a request for competitive proposals. The statutory authority for this sole-source procurement is FAR 13.106-1(b)(1). This notice of intent is not a request for competitive proposals. Interested parties that believes it can meet the requirement, may submit a capability statement to Mrs. Yolanda Rankin at yolanda.rankin@fda.hhs.gov before May 8, 2020 at 12:00 pm Central Standard Time (CST). A determination not to compete this requirement, based upon responses to this notice, is solely within the discretion of the Government. If no responsive statements are received before the closing date and time, an award will subsequently be made to Oxford Nanopore Technologies.
 

Web Link

SAM.gov Permalink
(https://beta.sam.gov/opp/3fd762da059d4b40a09648c32c8f0799/view)
 

Place of Performance

Address: Silver Spring, MD 20993, USA

Zip Code: 20993

Country: USA
 

Record

SN05637898-F 20200430/200428230145 (samdaily.us)
 

Source

SAM.gov Link to This Notice
(may not be valid after Archive Date)

---

| FSG Index  |  This Issue's Index  |  Today's SAM Daily Index Page |